scorecardresearch
Add as a preferred source on Google
Friday, November 21, 2025
TopicNovo Nordisk

Topic: Novo Nordisk

In battle for Indian anti-obesity market, Eli Lilly’s pre-filled pen on one side, Novo Nordisk’s on other

India's anti-obesity drug market is currently valued at Rs 3,000-3,500 crore & is projected to grow nearly eightfold by 2030, according to market estimates.

Eli Lilly announces trial results for world’s 2nd weekly insulin, aims for launch by year-end

New Delhi: There is excitement and hope in the insulin market the world over after U.S. based pharma giant Eli Lilly & Company on...

Ozempic on steroids? Successor that could cut down weight in half the time coming soon

While Novo Nordisk says CagriSema will help users lose up to 25% of weight, duration will be clear when final results of its effectiveness in obesity management come out in 3 months.

On Camera

Hasina’s was a trial in absentia, but not a trial without justice

The Sheikh Hasina trial represents an inflection point in the struggle to place citizens above rulers and prevent the next massacre.

At Charcha 2025: Local entrepreneurship, not just big IT, will drive next wave of distributed AI work

While global corporations setting up GCCs in India continue to express confidence in availability of skilled AI engineers, the panel argued that India’s real challenge lies elsewhere.

Can’t stay behind tech curve anymore, must catch up—Vice Chief of Navy Staff ahead of Swavlamban 2025

New Delhi: Noting that India cannot afford to stay behind the technology curve when it comes to war-fighting, Vice Chief of the Naval Staff...

INDIA has a Congress-sized hole. And the fix begins with a little humility

Without a Congress revival, there can be no challenge to the BJP pan-nationally. Modi’s party is growing, and almost entirely at the cost of the Congress.